Search Results - clinical+and+disease+specializations+%3e+oncology

365 Results

Sort By:

PSMA-targeted Nanoparticles for Therapy of Prostate Cancer

PSMA-targeting nanoparticle for prostate cancer therapyJHU Ref #: C10180Value Proposition:· Engineered nanoparticle system with potent urea-based PSMA inhibitor· Drug loaded nanoparticle· Specific and selective tumor cytotoxicity Unmet NeedProstate cancer affects millions of men globally and is a leading cause of cancer death in...

Published: 1/22/2026 | Inventor(s): Martin Pomper, Ronnie Mease, Sachin Chandran, Sangeeta Ray, Samuel Denmeade

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Immune Cell Modulation using Phosphodiesterase Activating Drug

Value PropositionAdjuvant to support the widespread use of immunotherapy in cancer.May improve the responses to checkpoint inhibitors (Keytruda) or CAR T cell activity.Diverse applications as a supplement to various precision cancer therapies.Repurposes a commercially available chemical compound for cancer treatment.Scalable synthesis, given the existing...

Published: 1/22/2026 | Inventor(s): Christopher Jackson, Landon Hansen, Eli Yazigi, Henry Brem

Keywords(s):

Category(s): Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology

RASAL1 and PTEN Co-Alterations Predict Cancer Aggressiveness

Value Proposition· Improved Prognostic Accuracy: Dual detection of RASAL1 and PTEN alterations enables highly accurate identification of aggressive cancers and risk stratification. These biomarkers provide greater precision in identifying aggressive cancers compared to established markers, enabling better patient management. · Pan-Cancer...

Published: 1/22/2026 | Inventor(s): Michael Xing, Xiaopei Shen, Jie Tan

Keywords(s):

Category(s): Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Companion Diagnostics, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > Precision Medicine Tools, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Diagnostics > Prognostics Biomarkers, Clinical and Disease Specializations > Oncology

A Novel-fate Marking Strategy to Permanently Tag Hypoxic Cancer Cells

Value Proposition· Permanently labels cells that have experienced hypoxia, enabling long-term tracking· Captures tumor evolution by identifying cells with past hypoxia exposure, not just at the time of tissue collection· Enables investigation of metastasis by tracking cells from hypoxic niches that may retain aggressive phenotypes· Supports...

Published: 1/22/2026 | Inventor(s): Daniele Gilkes, Ines Godet

Keywords(s): Breast Cancer, Cancers, Cardiovascular Diseases, Cell Lines, Discovery/Research Tools, Disease Indication, Human Cell Lines, In Vitro Research Tool, In Vivo Research Tool, Mouse Model, Translational Research Biomarker

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Cell Lines

Targeted chemo-immunotherapy delivery

Value PropositionEnhanced effect of immunotherapyTreatment for recurrent or metastatic diseaseImproved glioma treatment Unmet NeedImmunotherapy represents a new paradigm in cancer treatment. Molecules that effectively reverse the immune suppressing nature of cancer have the potential to enhance the body’s ability to work systemically combat cancer (Pardoll,...

Published: 1/22/2026 | Inventor(s): Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities

Mimetic peptides derived from collagen type IV for the treatment of angiogenesis-dependent diseases

C11348: Novel Anti-Angiogenic Collagen Derived Mimetic PeptidesNovelty:modified peptides from collagen IV derived parent peptide Pentastatin-1Value Proposition:The invention describes the synthesis of novel anti-angiogenic by substituting particular amino acids of the peptide Pentastatin-1 derived from collagen IV. Other advantages include:• Ability...

Published: 1/22/2026 | Inventor(s): Niranjan Pandey, Elena Rosca, Corban Rivera, Jacob Koskimaki, Amir Tamiz, Aleksander Popel

Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Protein, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

Monoclonal Antibody for Cancer Metastasis

Unmet Need· It is projected that there will be about 1.9 million cancer cases, and 6 thousand cancer deaths within the US in the year 2023 (Siegel, 2021). mAb immunotherapy has been found to be less damaging and less invasive to rapidly dividing normal tissues when compared to current tumor therapy treatments such as surgery, radiation, and chemotherapy....

Published: 1/22/2026 | Inventor(s): Andrew Ewald, Matthew Dunworth, Shannon Radomski, Livia Casciola-Rosen, Antony Rosen

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > Biomarkers, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Project Wonder Logo and Movie

Value Proposition· Video displaying how Project Wonder enables clustering, sorting, and filtering of data to find and visualize predictors of clinical outcomes Technology DescriptionResearchers at Johns Hopkins and Applied Physics Laboratories have developed a web-based dashboard for enabling physicians to parse patient populations and visualize...

Published: 1/22/2026 | Inventor(s): Antony Rosen, Christopher Mecoli, Suma Subbarao, Steve Smith, Kristina Liu

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Research Tools, Technology Classifications > Computers, Electronics & Software > Healthcare IT, Technology Classifications > Computers, Electronics & Software > Precision Medicine Tools, Technology Classifications > Research Tools > Bioinformatics

Anti-Fungal Drug Analogs to Treat Cancer by Preventing Angiogenesis and Hedgehog Pathway Activity

Value Proposition· Itraconazole is in clinical trials for cancer treatment as it is known to have antiangiogenic activity and anti-Hedgehog pathway activity, but its use has been limited by its potent inhibition of the drug metabolizing enzyme CYP3A4· The designed analog for itraconazole has greater antiangiogenic potency without CYP3A4 inhibition...

Published: 1/22/2026 | Inventor(s): Jun Liu, Wei Shi, Kalyan Kumar Pasunooti, Wukun Liu, Ruojing Li, Sarah Head, Yingjun Li

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Eye Disorders, Macular Degeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Ophthalmology > Macular Degeneration

Proinflammatory Immature Myeloid Cells and Their Use in Treatment of Cancer

Value Proposition:· Gene-editing approach creates myeloid cells polarized into a pro-inflammatory phenotype.· Engineered cells persist even in an immune-suppressive environment. · High potential as anti-cancer therapy, as cells are present in all tissues and can easily infiltrate tumors. · Cells demonstrate robust expression of pre-inflammatory...

Published: 1/22/2026 | Inventor(s): Alan Friedman

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Gene Therapies, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Immuno-Oncology

1 2 3 4 5 6 7 8 9 10 ...